Object-Platelet isoprostane 8-ISO-prostaglandin F2␣ (8-iso-PGF2␣), a proaggregating molecule, is believed to derive from nonenzymatic oxidation of arachidonic acid. We hypothesized that NADPH is implicated in isoprostane formation and platelet activation. Methods and Results-We studied 8-iso-PGF2␣ in platelets from 8 male patients with hereditary deficiency of gp91 phox , the catalytic subunit of NADPH oxidase, and 8 male controls. On stimulation, platelets from controls produced 8-iso-PGF2␣, which was inhibited Ϫ8% by aspirin and Ϫ58% by a specific inhibitor of gp91 phox . Platelets from patients with gp91
on the hereditary deficiency of gp91 phox , the catalytic subunit of NADPH oxidase. 2, 11, 14 In a previous study conducted in patients who were genetically deficient for gp91 phox , we have shown that urinary excretion of 8-iso-PGF2␣ was reduced compared with controls. 15 On the basis of this finding, we hypothesized that NADPH oxidase activation could have a role in platelet 8-iso-PGF2␣ formation. To explore this hypothesis, we conducted a study in male patients with X-linked chronic granulomatous disease (X-CGD) to see the behavior of platelet 8-iso-PGF2␣ formation compared with healthy controls. Also, we performed functional studies to further investigate the role of 8-iso-PGF2␣ in platelet activation. Thus, there is consistent evidence on the proaggregating activity of 8-iso-PGF2␣, 16, 17 but it has recently been questioned whether F2-isoprostanes could have a biological effect in vivo. 18 Here we show for the first time that platelet 8-iso-PGF2␣ derives prevalently from NADPH oxidase-dependent AA oxidation and plays a pivotal role in the process of platelet recruitment.
Materials and Methods
All materials were from Sigma Aldrich unless otherwise specified.
Subjects
We studied 8 recently identified male patients (aged 27Ϯ2.5 years) with hereditary deficiency of gp91 phox that was diagnosed as previously described. 2 X-CGD is a rare (prevalence, 1 in 1 000 000 individuals) primary immunodeficiency affecting the innate immunologic system and characterized by life-threatening bacterial and fungal infections. 19 It is caused by mutations in any of the 4 genes encoding subunits of the O 2 Ϫ -generating NADPH oxidase, resulting in defective O 2 Ϫ generation and intracellular killing. 13 None of X-CGD patients had a clinical history complicated by bleeding disorders. Eight healthy volunteers matched for sex, age, and risk factors of atherosclerosis were recruited from the same geographic area (Table) .
Platelet Preparation
To obtain platelet-rich plasma (PRP), samples were centrifuged for 15 minutes at 180g. To avoid leukocyte contamination, only the top 75% of the PRP was collected. Platelet pellets were suspended in HEPES buffer, pH 7.4 (2ϫ10 8 platelets/mL, unless otherwise noted).
Polymorphonuclear Leukocyte Preparation
Polymorphonuclear leukocytes (PMNs) were isolated from freshly taken EDTA blood from healthy volunteers by dextran-enhanced sedimentation of red blood cells, Ficoll-Histopaque density centrifugation, lysis of remaining erythrocytes with distilled water, and washing of cells with Hanks' balanced salt solution in the absence of any divalent cations.
Evaluation of OFR
Cell suspension was incubated with 2Ј,7Ј-dichlorofluorescin diacetate (5 mol/L) for 15 minutes at 37°C. After incubation, PMNs were treated with phorbol myristate acetate (PMA) (10 mol/L), and platelets were activated with AA (1 mmol/L) in the presence or absence of the gp91 phox -specific blocking peptide (gp91ds-tat, 50 mol/L) or its control peptide tat (50 mol/L). 20 Basal OFR level in resting cells was expressed as mean fluorescence, and OFR production in stimulated cells was expressed as stimulation index (mean level of fluorescence in stimulated cells/mean level of fluorescence in unstimulated cells).
Platelet Aggregation
Platelet aggregation was induced by subthreshold (0.1 to 0.5 g/mL) or threshold (2.0 g/mL) doses of collagen (Mascia Brunelli) or AA (subthresholdϭ0.1 to 0.5 mmol/L; thresholdϭ1.0 mmol/L) and measured as previously described 21 in the presence or absence of 8-iso-PGF2␣ (1 to 1000 pmol/L). Threshold concentration of the agonist was defined as the lowest concentration of the agonist that elicits Ͼ50% increase in light transmission difference between PRP and platelet-poor plasma 5 minutes after the addition of the agonist. 22 A subthreshold concentration of agonist was defined as the highest concentration of the agonist that elicited Ͻ20% platelet aggregation.
Platelet Recruitment
Platelet recruitment was performed with a method modified from that described by Krötz et al. 23 PRP samples were incubated (30 minutes. at 37°C) with or without NO synthase inhibitor nitro-Larginine methyl ester (L-NAME, 100 mol/L), gp91ds-tat (50 mol/ L), control peptide tat (50 mol/L), aspirin (COX-1 inhibitor, 100 mol/L), TxA 2 /isoprostanes receptor inhibitor (SQ29548, 0.1 mol/L), catalase (500 U/mL), superoxide dismutase (PEG-SOD), (300 U/mL), apocynin (100 mol/L), 2,3-dimethoxy-1,4-naphthoquinone (DMNQ) (OFR generator, 100 mol/L), the ADP scavenger apyrase (2 U/mL), the lipoxygenase (LOX) inhibitor 5,8,11,14-eicosatetraynoic acid (ETYA; 10 mol/L), and the xanthine oxidase inhibitor allopurinol (10 mol/L), before activation with collagen (2 g/mL) in the presence or absence of 8-iso-PGF2␣ (1 to 1000 pmol/L) (Calbiochem). Collagen-induced platelet aggregation was measured for 10 minutes. Then, an equal portion of untreated platelets was added to each tube, which increased the density of the solution and hence caused a reduction in light transmission. Aggregation of the newly added platelet portion in the presence of an existing aggregate was then measured for 5 minutes and expressed as a percentage of the aggregation that had been initially reached.
Platelet recruitment was also induced by another method using the supernatant of activated platelets from healthy subjects and X-CGD as agonists. Briefly, collagen-induced platelet aggregation was stopped after 10 minutes, samples were immediately pelleted at 4°C, and the supernatant was used as agonist according to Valles et al. 24 The concentration in the final suspensions was adjusted to 2ϫ10 8 platelets/mL. Aggregation was measured as increase in percentage of light transmission as reported above.
Platelet Thrombus Formation on Fibrillar Collagen Type I on Blood Perfusion

Thrombus Formation Ex Vivo
A glass coverslip was coated with acid-insoluble type I collagen (Sigma-Aldrich, St. Louis, Mo) and assembled at the bottom of a rectangular flow chamber on the stage of an inverted fluorescence microscope equipped with a confocal module (TCS SP5, Leica, Milan, Italy). Platelets in whole blood anticoagulated with FPRchloromethylketone (50 mol/L) were rendered fluorescent with 
Thrombus Volume Measurement
The area of the field of view seen through the ϫ20 objective and the video camera used was 207,025 m 2 . Total thrombus volume per field of view, reflecting the number of aggregated platelets, was calculated as the sum of the surface area covered by platelets in each individual confocal section multiplied by the z-axis interval (0.94 m) between adjacent sections, as reported Savage et al. 25 The threshold between signal and image background was established using an unbiased algorithm. Image analysis was performed with Image J (http://rsbweb.nih.gov/ij/).
Platelet and Serum TxA 2
AA (1 mmol/L)-activated PRP samples were centrifuged, and platelet-poor plasma was stored at Ϫ80°C. Serum TxA 2 was evaluated in blood samples kept for 60 minutes at 37°C and centrifuged at 300g before storage at Ϫ80°C. Platelet TxA 2 and serum TxA 2 were analyzed as previously described. 26, 27 Briefly, platelet TxA 2 and serum TxA 2 were measured with or without aspirin (100 mol/L) by evaluating its stable metabolite TxB 2 by an enzyme immunoassay (EIA) commercial kit (Amersham Pharmacia, Biotech, Little Chalfont, United Kingdom) and expressed as pg/10 8 cells or ng/mL, respectively. Intra-and interassay coefficients of variation for TxB 2 EIA kit were 4.0% and 3.6%, respectively.
8-Iso-PGF2␣ Assays
To evaluate platelet 8-iso-PGF2␣ formation, PRP was centrifuged 20 minutes at 300g to concentrate platelets, and the pellet was suspended in Tyrode buffer (final platelet concentration of 2ϫ10 8 /mL). Platelet suspensions were incubated with or without AA (1 mmol/L) in presence or absence of gp91ds-tat (50 mol/L), control peptide tat (50 mol/L), catalase (500 U/mL), superoxide dismutase (PEG-SOD, 300 U/mL), apocynin (100 mol/L), allopurinol (10 mol/L), ETYA (10 mol/L), L-NAME (100 mol/L), and ASA (100 mol/L) for 15 minutes at 37°C. After incubation, platelets were pelleted 3 minutes at 300g. 8-iso-PGF2␣ content was measured by gas chromatography as previously described 28 and expressed in pmol/L.
Plasma 8-Iso-PGF2␣ Assays
8-iso-PGF2␣ formation was also evaluated in the supernatant of samples from shear-induced thrombus formation. Whole blood samples were centrifuged (10 minutes, 300g), and the supernatant was treated as reported above and expressed as pmol/L.
Flow Cytometry Analysis of gpIIb/IIIa
PAC1 is an antibody that recognizes an epitope on the glycoprotein IIb/IIIa (gpIIb/IIIa) of activated platelets, at or near the platelet fibrinogen receptor. PAC1 binding on platelet membrane was analyzed using the specific fluorescein isothiocyanate-labeled monoclonal antibody anti-PAC1 (BD International) as previously reported. 26 All assays included samples to which an irrelevant isotype-matched antibody (fluorescein isothiocyanate-labeled IgM) was added. To analyze PAC1 binding, PRP was incubated 30 minutes at 37°C with or without 8-iso-PGF2␣ (1 to 1000 pmol/L) (Calbiochem), collagen (0.5 to 2.0 g/mL), AA (0.1 to 1.0 mmol/L), or a combination thereof. In some experiments, platelets were also treated with the TxA 2 /isoprostane receptor antagonist SQ29548 (0.1 mol/L) or L-NAME (100 mol/L). Fluorescence intensity was analyzed on an Epics XL-MCL Cytometer (Coulter Electronics) equipped with an argon laser at 488 nmol/L. For every histogram, 5ϫ10 4 platelets were counted to evaluate the percentage of positive platelets. Antibody reactivity is reported as mean fluorescence intensity.
Cytoplasmic Free Calcium Mobilization
Cytoplasmic free calcium mobilization was evaluated according to Labiós et al. 29 Briefly, CD61PE (specific monoclonal antibody to platelet GPIIIa, Pharmingen) and 250 AM fluo-3-acetoxymethyl ester (FLUO 3-AM, calcium probe, Molecular Probes, Leiden, the Netherlands) were added to the sample. The basal fluorescence intensity corresponding to FLUO 3-AM (FL1 log) was measured for 15 seconds in the platelet population identified in the gate forward scat log/side scat log as CD61-positive events. Platelet stimulation with thrombin (0.1 U/mL) was used as positive control. Changes in fluorescence were evaluated in arbitrary units as fold increase in calcium mobilization. Samples were incubated for 30 minutes at 37°C with or without 8-iso-PGF2␣ (1 to 1000 pmol/L) or collagen (0.5 to 2.0 g/mL) and AA (0.1 to 1.0 mmol/L). In some experiments, platelets were also treated with SQ29548 (0.1 mol/L) or L-NAME (100 mol/L). To further evaluate the role of calcium we incubated platelets with 1,2-bis(2-aminophenoxy)ethane-N,N,NЈ,NЈ-tetraacetic acid (200 mol/L), a calcium chelator, before thrombin or 8-iso-PGF2␣-induced platelet activation.
Platelet Nitrite and Nitrate Measurement
A colorimetric assay kit (Tema Ricerca) was used to determine the nitric oxide metabolites nitrite and nitrate (NOx) in the supernatant of recruited platelet in presence or absence of L-NAME or gp91ds-tat (50 mol/L) or control peptide tat (50 mol/L) at 37°C for 15 minutes as previously described. 30 Intra-and interassay coefficients of variation were 2.9% and 1.7%, respectively.
Membrane and Cytoplasmic Protein Extraction
To analyze the specificity of gp91ds-tat in blocking platelets NADPH oxidase activation, the effect of this peptide was analyzed on the translocation of p47 phox from cytosol to membranes in AA (1 mmol/L)-activated platelet according to Fortuño et al. 31 Briefly, the extraction of membrane and cytoplasmic proteins was performed by using the ProteoJET Membrane Protein Extraction Kit (Fermentas International Inc). 31 The extraction was performed in 3 steps: cell harvesting and permeabilization, extraction of cytoplasmic proteins, and extraction of membrane proteins.
Electrophoresis and Immunoblotting of Membrane and Cytoplamic p47 phox
Equal amounts of protein (130 g/lane) estimated by Bradford assay were solubilized in a 2ϫ Laemmli sample buffer containing 2-mercaptoethanol and loaded in a denaturing SDS/10% polyacrylamide gel. Western blot analysis was performed with monoclonal anti-p47 phox (2 g/mL) incubated overnight at 4°C. After incubation, the pure nitrocellulose membranes (0.45 m) were washed and incubated with goat anti-mouse IgG1-horseradish peroxidase for 2 hours. Immune complexes were detected by enhanced chemiluminescence. The developed spots were calculated by densitometric analysis on a NIH Image 1.62f analyzer, and the value was expressed in arbitrary units. Each sample was analyzed in triplicate.
Urinary 8-Iso-PGF2␣ Assays
Urinary 8-iso-PGF2␣ was measured by a previously described and validated EIA assay method. 32 Ten milliliters of urine was extracted on a C-18 solid phase extraction column; the purification was tested for recovery by adding a radioactive tracer (tritiated 8-iso-PGF2␣) (Cayman Chemical). The eluates were dried under nitrogen, recovered with 1 mL of buffer, and assayed in a PGF2␣-III specific EIA kit (Cayman Chemical). Urinary 8-iso-PGF2␣ concentration was corrected for recovery and creatinine excretion and expressed as pg/mg of creatinine. Intra-and interassay coefficients of variation were 2.1% and 4.5%, respectively.
ATP Release
Platelet activation (collagen, 2 g/mL) was stopped after 2 minutes by addition of formaldehyde/EDTA according to Costa and Murphy. 33 After centrifugation at 300g for 30 seconds, the ATP concen-tration in the supernatant was measured on a LKB 1251 luminometer (Pharmacia, Uppsala, Sweden) by addition of luciferin (40 mg/mL) and luciferase (880 U/mL) (both by Chronolog Corp, Havertown, Pa) according to Holmsen et al. 34 The results were expressed as M/10 5 platelets, comparing the luminescence detected with that measured by a standard curve. The standard curve was obtained by evaluating the luminescence resulting by adding scalar concentrations of ATP (0.5, 1, and 2 mol/L) to the buffer.
Statistical Analysis
Data are reported as meanϮSD. The comparison between variables in the in vitro and ex vivo studies was made by the Student t test for paired and unpaired data. The data were also confirmed by nonparametric test. Bivariate analysis was performed with a Spearman correlation test. Significance was accepted at PϽ0.05.
Results
Clinical characteristics of the population studied are reported in the Table. Risk factors of atherosclerosis were similar in patients and controls. All subjects were nonsmoking.
OFR Production in PMNs and Platelets
For the purpose of assessing whether blocking gp91 phox by its specific peptide, gp91ds-tat, inhibited the activity of NADPH oxidase, we stimulated PMNs and platelets from healthy subjects with PMA and AA, respectively, in the presence or absence of gp91ds-tat or the control peptide (tat). Treatment with gp91ds-tat resulted in 50% and 65% reduction of PMA-induced and AA-induced OFR production, respectively ( Figure 1 ). No change of OFR production was observed in samples treated with the control peptide tat (data not shown).
Platelet Activation in Healthy Subjects and X-CGD Patients
Collagen (2 g/mL)-and AA (1 mmol/L)-induced platelet aggregation were similar in healthy subjects and X-CGD patients. Platelet incubation with 8-iso-PGF2␣ (1 to 100 pmol/L) did not change platelet aggregation in either patients or healthy subjects (Figure 2A ).
AA (1 mmol/L)-induced platelet activation elicited a similar amount of TxB 2 , the stable metabolite of TxA 2 , in healthy subjects and X-CGD patients. Aspirin reduced platelet TxB 2 formation by more than 95% (PϽ0.001) in both healthy subjects and X-CGD patients; conversely, no change of platelet TxB 2 was observed in samples treated with gp91ds-tat ( Figure 2B ).
AA-induced platelet 8-iso-PGF2␣ formation was significantly lower in X-CGD patients compared with healthy subjects ( Figure 2C ) (PϽ0.001). In platelets from healthy subjects, AA-induced platelet 8-iso-PGF2␣ formation was marginally reduced by aspirin (Pϭnot significant [NS]), ETYA (PϭNS), L-NAME (PϭNS), and allopurinol (PϭNS), whereas it was significantly inhibited by gp91ds-tat (PϽ0.001), catalase (PϽ0.001), PEG-SOD (PϽ0.001), and apocynin (PϽ0.001) ( Figure 2C ). Incubation of platelets with control peptide tat did not influence 8-iso-PGF2␣ formation (PϭNS). gp91ds-tat and acetylsalicylic acid (ASA) did not modify 8-iso-PGF2␣ formation in X-CGD patients ( Figure  2C ). Serum TxB 2 was in the same range in healthy subjects and X-CGD patients (455.4Ϯ10.6 versus 445.0Ϯ11.6 ng/mL, respectively, PϭNS) Consistent with platelet findings, systemic concentration of 8-iso-PGF2␣, as assessed by urinary excretion of 8-iso-PGF2␣, was depressed in X-CGD compared with healthy subjects (65Ϯ5.4 versus 132Ϯ30.5 pg/mg creatinine, respectively, PϽ0.001).
Platelets from healthy subjects and X-CGD released similar amounts of ATP on stimulation with collagen (0.86Ϯ0.10 and 0.82Ϯ0.06 mol/L per 10 5 platelets, respectively, PϭNS) ( Figure 2D ).
Platelet NOx in Healthy Subjects and X-CGD Patients
Platelet NOx was evaluated with or without L-NAME or gp91ds-tat in patients and healthy subjects ( Figure 2E ). Platelets from X-CGD produced a significantly higher , catalase (500 U/mL), PEG-SOD (300 U/mL), allopurinol (10 mol/L), ETYA (10 mol/L), L-NAME (100 mol/L), or apocynin (100 mol/L). D, ATP release in collagen-stimulated platelets from healthy subjects and X-CGD patient (PϭNS). E, Platelet NOx production in agonist-stimulated platelets treated or not with the NO synthase inhibitor L-NAME (100 mol/L), gp91ds-tat (50 mol/L), or control tat peptide (50 mol/L). Experiments were performed in samples from 8 healthy subjects and 8 X-CGD (*PϽ0.001, **Pϭ0.05).
amount of NOx compared with healthy subjects (PϽ0.001). Incubation of platelets with L-NAME elicited a significant reduction of NOx, which was more marked in X-CGD patients (Ϫ72%, PϽ0.001) compared with healthy subjects (Ϫ55%, PϽ0.001). Incubation of platelets with gp91ds-tat enhanced NOx only in platelets from healthy subjects (PϽ0.05). Incubation of platelets with control peptide tat did not influence platelet NOx ( Figure 2E ).
Platelet Activation by 8-Iso-PGF2␣ in Healthy Subjects
8-iso-PGF2␣ increased platelet aggregation to Ͼ20% but Ͻ50% light transmission only at 100 pmol/L. Similarly, 8-iso-PGF2␣ dose-dependently increased gpIIb/IIIa activation and calcium mobilization (Figures 3 to 5) . The higher 8-iso-PGF2␣ concentration of 1000 pmol/L was less effective compared with 100 pmol/L (not shown). When 100 pmol/L 8-iso-PGF2␣ was combined with a subthreshold concentration of agonists, platelet aggregation was above 50%, suggesting that 8-iso-PGF2␣ potentiated the aggregating property of collagen (PϽ0.001) and AA (PϽ0.001) ( Figure 3A) .
Representative tracings of platelet aggregation with a subthreshold concentration of agonists and 8-iso-PGF2␣ are reported in Figure 3C .
Similarly, 100 pmol/L 8-iso-PGF2␣ potentiated gpIIb/IIIa activation and calcium mobilization elicited by a subthreshold concentration of the agonists ( Figure 4A and 4D) .
The increase in platelet aggregation ( Figure 3A) , gpIIb/IIIa activation ( Figure 4A) , and Ca 2ϩ mobilization ( Figure 4D) elicited by 8-iso-PGF2␣ (100 pmol/L) and a subthreshold concentration of AA was unaffected by L-NAME (100 mol/L) but significantly inhibited by SQ28548 (Figures 3A , 4A, and 4D).
Platelet Activation by 8-iso-PGF2␣ in X-CGD
The increase in platelet activation by 8-iso-PGF2␣ alone or in combination with a subthreshold concentration of agonists was observed also in X-CGD patients, in whom, however, the rate of platelet activation was lower than that observed with platelets from healthy subjects. Conversely, the increase in platelet aggregation ( Figure 3B ), gpIIb/IIIa activation ( Figure  4B ), and calcium mobilization ( Figure 4E ) by L-NAME was significantly increased in X-CGD compared with control.
Platelet Recruitment and 8-iso-PGF2␣
Platelets from healthy subjects incubated with 8-iso-PGF2␣ (1 to 100 pmol/L) showed a dose-dependent increase in platelet recruitment ( Figure 5A ); treatment with 1000 pmol/L 8-iso-PGF2␣ did not increase platelet recruitment compared with control (not shown). 8-iso-PGF2␣ (100 pmol/L)-induced platelet recruitment was weakly enhanced by L-NAME (Pϭ0.05) and significantly inhibited by SQ29548 (PϽ0.001) and apyrase (PϽ0.001) ( Figure 5A ). Incubation with SQ29548 and apyrase almost completely abolished 8-iso-PGF2␣ (100 pmol/L)-induced platelet recruitment ( Figure 5A ). Platelet recruitment was almost completely absent in X-CGD patients (4Ϯ1% in X-CGD versus 50Ϯ3% in controls PϽ0.001) and was partially restored by platelet incuba- tion with 100 pmol/L 8-iso-PGF2␣ (Pϭ0.05) ( Figure 5B ). Treatment with L-NAME further enhanced 8-iso-PGF2␣ (100 pmol/L)-induced platelet recruitment (PϽ0.001) ( Figure  5B ). SQ29548 and apyrase significantly inhibited 8-iso-PGF2␣-induced platelet recruitment (PϽ0.001) ( Figure 5B).
Platelet recruitment was also analyzed by adding the supernatant of agonist-stimulated platelets from HS and X-CGD to platelets from HS or X-CGD. Although the supernatant of collagen-stimulated platelets from HS induced aggregation Ͼ50% when added to fresh platelets from both . gpIIb/IIIa activation and cytoplasmic free calcium mobilization induced by 8-iso-PGF2␣ (1 to 100 pmol/L), collagen (0.5 g/mL), AA (0.1 mmol/L), the 2 agonists in the presence of 8-iso-PGF2␣ (100 pmol/L), and AA plus 8-iso-PGF2␣ added with SQ29548 (0.1 mol/L) or L-NAME (100 mol/L) in 8 healthy subjects (A and D) and 8 X-CGD patients (B and E) (*PϽ0.001). C and F, Representative flow cytometric analysis of the experiment in a healthy subject. Thrombin (0.1 U/mL) was used as positive control for calcium mobilization.
HS and X-CGD, the supernatant of collagen-stimulated platelets from X-CGD elicited aggregation Ͼ50% only if it was added with 8-iso-PGF2␣ ( Figure 3A and 3B) .
Effect of Aspirin, SQ29548, and Radical Scavenger on Platelet Function
As aspirin inhibits platelet TxA 2 formation 10 and SQ29548 antagonizes not only TXA 2 but also isoprostanes, 10 we investigated whether the 2 drugs affected recruitment of platelets from healthy subjects differently. Platelet recruitment was significantly inhibited by incubation of platelets with gp91ds-tat (PϽ0.001), catalase (PϽ0.001), the PEG-SOD (PϽ0.001), and apocynin (PϽ0.001) and significantly enhanced by 2,3-dimethoxy-1,4-naphthoquinone (PϽ0.001). ASA pretreatment induced a lower inhibition (Pϭ0.05) of platelet recruitment. The TxA 2 /isoprostane receptor inhibitor SQ29548 (PϽ0.001) significantly inhibited platelet recruitment in both controls and ASA-treated platelets (PϽ0.001) ( Figure 5D ). The LOX inhibitor ETYA and the xanthine oxidase inhibitor allopurinol only marginally affected platelet recruitment (PϽ0.05). Incubation of platelets with the control peptide tat did not influence platelet recruitment ( Figure 5D ).
Effect of gp91ds-tat and Apocynin on Platelet Thrombus Formation on a Collagen Type I Surface on Blood Perfusion at 1500 s
؊1
Thrombus formation on blood perfusion over insoluble fibrillar collagen type I at the wall shear rate of 1500 s Ϫ1 was studied on samples from HS. Thrombus volume increased progressively as a function of time. Using blood treated with gp91ds-tat, thrombus volume was reduced as compared with control at all time points and significantly reduced at 6 minutes. Similar findings were observed with apocynin, which, however, elicited a lower inhibitory effect as compared with gp91ds-tat ( Figure 6A and 6B) . Platelet recruitment with or without 8-iso-PGF2␣ (1 to 100 pmol/L) in samples added with or without L-NAME (100 mol/L) SQ29548 (0.1 mol/L), or apyrase (2 U/mL). Experiments were performed in samples from 8 healthy subjects (A) and 8 X-CGD patients (B). C, Representative slopes of platelet recruitment from a healthy subject. D, Platelet recruitment in samples from HS (nϭ8) added with or without ASA (100 mol/L), gp91ds-tat (50 mol/L), tat (50 mol/L), SQ29548 (0,1 mol/L), catalase (500 U/mL), PEG-SOD (300 U/mL), apocynin (100 mol/L), 2,3-dimethoxy-1,4-naphthoquinone (DMNQ, 100 mol/L), allopurinol (10 mol/L), and ETYA (10 mol/L) (*PϽ0.001, **PϽ0.05).
Thrombus formation was associated with isoprostane formation (350Ϯ30 pmol/L at 6 minutes) that was inhibited by treatment with gp91ds-tat (160Ϯ20 pmol/L at 6 minutes) and apocynin (150Ϯ15pmol/L at 6 minutes).
Effect of gp91phox ds-tat on p47 phox Translocation
To analyze the specificity of gp91 ds-tat in inhibiting platelet NADPH oxidase activation, we evaluated the effect of the translocation of p47 phox from the cytosol to the membrane of platelets from healthy subjects. The peptide was described as able to block the binding of the cytosolic p47 phox to the membrane subunit gp91
phox . 32 AA-induced p47 phox translocation was inhibited by platelet preincubation with gp91ds-tat (3.2Ϯ0.8-fold increase versus 5.1Ϯ0.2-fold increase, Ϫ38%, PϽ0.001) (Figure 6C and 6D) . The preincubation of AAstimulated platelets with the control peptide did not show any reduction of p47 phox translocation ( Figure 6C and 6D) .
Discussion
This study provides evidence that platelet isoprostane 8-iso-PGF2␣ is formed via activation of gp91 phox and contributes to the process of platelet recruitment by activating gpIIb/IIIa.
Previous studies have shown that on stimulation platelets release F2-isoprostanes, namely 8-iso-PGF2␣, in a concentration depending on the type of agonist used but usually in the range of 100 to 500 pmol/L. 17, 35, 36 In our experiments, the Figure 6 . A, Volume of platelet thrombi forming onto fibrillar collagen type I on blood perfusion at the shear rate of 1500 s Ϫ1 in samples from HS added with gp91ds-tat (50 mol/L) or apocynin (100 mol/L). Experiments were performed in samples from 3 healthy subjects (*Pϭ0.05). B, Single-frame images of platelet thrombi formed on a collagen type I surface on blood perfusion at 1500 s Ϫ1 . Images were taken from real-time video recordings after 6 minutes of blood perfusion. Detector settings were kept constant throughout the experiment; thus, the intensity of light on a gray scale from 0 (black) to 255 (white) is proportional to the number of fluorescent platelets on the surface. The 3 bottom images are enlargements (scale barϭ10 m) of the corresponding top ones (scale barϭ50 m). The images at lower magnification show that thrombus formation on the surface is homogeneous. The enlarged images show the thrombi formed in the presence of gp91ds-tat or apocynin have a less compact structure than thrombi formed in control blood and are constituted by fewer platelets. C, Densitometric evaluation of the membrane p47 phox content in platelets added with or without gp91ds-tat or tat before and after activation with AA in healthy subjects (nϭ5) (*PϽ0.001). D, A representative Western blot analysis of the membrane and cytosol 47 phox content in a healthy subject.
concentration of 8-iso-PGF2␣ released by normal platelets on stimulation with agonist was on the same order of magnitude. In experiments conducted in platelets from healthy subjects treated with aspirin, we observed a reduction of 8-iso-PGF2␣ by 8%, which is consistent with previous data showing a marginal role for COX-1 in the formation of this isoprostanes. 17 Conversely, a much higher inhibition (Ϫ58%) was observed with a specific inhibitor of gp91 phox , suggesting that NADPH oxidase has a major role in 8-iso-PGF2␣ formation. To explore this hypothesis, platelet 8-iso-PGF2␣ was measured in platelets taken from patients with hereditary deficiency of gp91 phox . We found that platelet 8-iso-PGF2␣ was significantly reduced in patients compared with controls, with a mean reduction of 75% (in the supernatant of AA -stimulated platelets), indicating that platelet generation of 8-iso-PGF2␣ is maximally dependent on nonenzymatic oxidation of AA via NADPH oxidase-generating O 2 Ϫ . The interplay between NADPH oxidase activation and F2-isoprostane formation was further corroborated by analysis of 8-iso-PGF2␣ urinary excretion, which reflects the systemic production of this isoprostane. 8 Thus, compared with healthy subjects, X-CGD patients have lower urinary excretion of 8-iso-PGF2␣, indicating that the low production of this isoprostane is likely to occur, not only in platelets but also in other cellular lines.
The simultaneous measurement of TxA 2 allowed us to compare the behavior of these 2 eicosanoids in the population studied. It is of note that on agonist stimulation, normal platelets produced both TxA 2 and 8-iso-PGF2␣. Unlike the case with 8-iso-PGF2␣, in X-CGD patients platelet formation of TxA 2 was unaffected, indicating that the activation of COX-1 is not influenced by OFR formation. Together, these data show that on stimulation platelets produce 2 eicosanoids via different pathways as TxA 2 derives exclusively from COX-1 activation, whereas 8-iso-PGF2␣ derives maximally from NADPH oxidase-dependent AA oxidation.
Although the role of TxA 2 in the activation of platelets is well established, data concerning the role of 8-iso-PGF2␣ is less clear. Previous studies have consistently shown that 8-iso-PGF2␣ does not induce platelet aggregation; conversely, it elicits shape change and amplifies the platelet response to common agonists. 16, 17 However, this effect and other biological activities, including vasoconstriction, mitogenesis of smooth muscle cells, and proliferation of fibroblasts, have been questioned because they have been achieved with supraphysiologic concentrations of F2-isoprostane. 18 In the present study, we could confirm that F2-isoprostanes actually amplify the platelet response to common agonists but at concentrations much lower than that previously used 16, 17 and in the same range produced by normal activated platelets.
To further explore the role of F2-isoprostane on platelet activation, we studied the effect of 8-iso-PGF2␣ in the process of platelet recruitment, which mimics in vivo accumulation of platelets at site of vascular injury; it is influenced by aggregating molecules, which propagate thrombus plug on release by platelets that originally initiated to aggregate. 23 Among these molecules, OFR seem to have an important role, as suggested by the fact that OFR scavengers or inhibitors of O 2 Ϫ production reduced platelet recruitment. 23 Consistent with these findings, O 2 Ϫ scavenger, apocynin, and catalase inhibited platelet recruitment, whereas an OFR donor such as DNMQ enhanced it. We also evaluated the effect of a direct NADPH oxidase inhibitor peptide, namely gp91ds-tat: this peptide is able to block the binding of the cytosolic NADPH oxidase subunit p47 phox to the membrane subunit gp91 phox in neutrophils. 32 Accordingly, gp91ds-tat prevented 47 phox binding to platelet gp91 phox and significantly inhibited both platelet recruitment and platelet 8-iso-PGF2␣ production, suggesting a potential role for 8-iso-PGF2␣ in the process of platelet propagation activation.
This hypothesis was strengthened by experiments performed in platelets from patients with X-CGD, in whom the reduced 8-iso-PGF2␣ production was associated with impaired platelet recruitment, and corroborated by a series of in vitro studies performed in normal platelets and platelets from X-CGD. In platelets from controls, a significant increase in platelet recruitment was observed when platelets were incubated with scalar concentration of 8-iso-PGF2␣. Also, incubation of platelets from X-CGD patients with 8-iso-PGF2␣ resulted in a partial restoration of platelet recruitment. To investigate the mechanism through which 8-iso-PGF2␣ enhanced platelet recruitment, we focused our attention on the gpIIb/IIIa, which has previously been shown to be activated by this isoprostane but at supraphysiologic concentrations. 16 We could confirm that even low 8-iso-PGF2␣ concentration actually enhanced the activation of gpIIb/IIIa. This effect seemed to be attributable to the mobilization of Ca 2ϩ , 37 which in fact was increased by 8-iso-PGF2␣ either in normal platelets or platelets from X-CGD patients. The fact that platelets from X-CGD patients demonstrated only a partial restoration of platelet recruitment, as well as gpIIb/IIIa activation, and Ca 2ϩ mobilization induced by isoprostane incubation suggested a more complex scenario in such a phase of platelet activation. Thus, we hypothesized that the reduced formation of O 2 Ϫ could result in higher NO generation 23 and eventually impaired platelet recruitment. 23 In support of the validity of such hypothesis, we demonstrated that platelet generation of NO was higher in X-CGD patients than in controls and that the incubation of normal platelets with gp91ds-tat resulted in higher NO generation. Also, platelet incubation with L-NAME, an inhibitor of NO synthase, 30 further enhanced recruitment of platelets incubated with isoprostanes with an effect that was much higher in X-CGD patients compared with healthy subjects. It is of note, however, that despite incubation with L-NAME and isoprostanes, platelet recruitment of X-CGD patients was not fully restored. This could be dependent on the fact that OFR production contributes to the expression of other molecules implicated in platelet activation, such as CD40L, which are lowered coincidentally with NADPH oxidase downregulation. 2, 38 It is well established that Tx receptors are activated not only by TxA 2 but also by F2-isoprostanes. 16, 39 We therefore investigated whether blockade of COX-1 or Tx receptors had a different impact in the process of platelet recruitment. The study showed that incubation with aspirin reduced platelet recruitment by 17%, an effect that was lower than that observed with SQ29548 (Ϫ64%), a specific inhibitor of Tx/isoprostane receptors. This finding can be explained by the fact that aspirin inhibits TxA 2 but scarcely influences isoprostane formation, whereas SQ29548 was likely to functionally blunt not only TxA 2 but also 8-iso-PGF2␣. In accordance with this hypothesis, SQ29548 prevented platelet activation elicited by isoprostanes.
The results of this study have implications and limitations. The fact that 8-iso-PGF2␣ promotes propagation of platelet activation at physiological concentration indicates that this isoprostane is a biologically active compound that may be relevant in the process of thrombus growth. The different chemical stability of TxA 2 and 8-iso-PGF2␣ may suggest a different role for these 2 eicosanoids in the process of platelet activation. It is, therefore, conceivable that TxA 2 , because of its chemical instability, is a rapid and immediate agonist that is useful in the early phase of platelet activation. Conversely, 8-iso-PGF2␣, because of its chemical stability, is an eicosanoid reservoir that may be useful in the late phase of platelet aggregation propagation. Such a hypothesis is in agreement with the observation that thrombus formation in blood perfused over fibrillar collagen type I at 1500 s Ϫ1 was reduced in the presence of NADPH oxidase inhibitors that impaired isoprostane formation. Of note, impaired platelet isoprostane formation had no influence on platelet adhesion to collagen or the initial phase of aggregation, a finding that may explain the absence of bleeding in X-CGD patients. The fact that the Tx/isoprostane receptor inhibitor was more effective than aspirin in inhibiting platelet recruitment may have relevant pharmacological consequences, as it suggests that blocking Tx/isoprostane receptors could more favorably influence thrombus formation and propagation. This was likely to occur in virtue of a "dual" antiplatelet effect, ie, antagonism of both TxA 2 and 8-iso-PGF2␣, but this hypothesis needs to be further investigated in other experimental models. A limitation of the study is that we focused our study on the analysis of platelet 8-iso-PGF2␣, and we did not investigate whether other isoprostanes may have a role in the process of platelet recruitment. Further study should be done to analyze this issue.
In conclusion, this study shows that platelet formation of 8-iso-PGF2␣ is maximally dependent on nonenzymatic oxidation of AA via gp91 phox -dependent OFR generation. The interplay between platelet formation of 8-iso-PGF2␣ and platelet recruitment via activation of gpIIb/IIIa may give new insight into the mechanism through which inflammation and oxidative stress contribute to platelet activation and thrombosis.
Sources of Funding
This study was supported by Ateneo 2007 University of Rome "La Sapienza" (to F.V.).
